Int. J. Environ. Res. Public Health 2012, 9 1951 14. Towatari, M.; Iida, H.; Tanimoto, M.; Iwata, H.; Hamaguchi, M.; Saito, H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997, 11, 479–484. 15. Simon, M.; Grandage, V.L.; Linch, D.C.; Khwaja, A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005, 24, 2410–2420. 16. Casado, F.L.; Singh, K.P.; Gasiewicz, T.A. The aryl hydrocarbon receptor: Regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol. Dis. 2010, 44, 199–206. 17. Hayashibara, T.; Yamada, Y.; Mori, N.; Harasawa, H.; Sugahara, K.; Miyanishi, T.; Kamihira, S.; Tomonaga, M. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: Constitutive activation of AhR in ATL. Biochem. Biophys. Res. Commun. 2003, 300, 128–134. 18. McHale, C.M.; Zhang, L.; Smith, M.T. Current understanding of the mechanism of benzene-induced leukemia in humans: Implications for risk assessment. Carcinogenesis 2012, 33, 240–252. 19. Schwind, S.; Maharry, K.; Radmacher, M.D.; Mrózek, K.; Holland, K.B.; Margeson, D.; Whitman, S.P.; Hickey, C.; Becker, H.; Metzeler, K.H.; et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J. Clin. Oncol. 2010, 28, 5257–5264. 20. Havelange, V.; Stauffer, N.; Heaphy, C.C.; Volinia, S.; Andreeff, M.; Marcucci, G.; Croce, C.M.; Garzon, R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 2011, 117, 4696–4706. 21. National Center for Biotechnology Information. Gene Expression Omnibus GSE15061. 2011. Available online: http://www.ncbi.nlm.nih.gov/geo/ (accessed on 19 December 2011). 22. Mills, K.I.; Kohlmann, A.; Williams, P.M.; Wieczorek, L.; Liu, W.M.; Li, R.; Wei, W.; Bowen, D.T.; Loeffler, H.; Hernandez, J.M.; et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114, 1063–1072. 23. Haferlach, T.; Kohlmann, A.; Wieczorek, L.; Basso, G.; Kronnie, G.T.; Béné, M.C.; De Vos, J.; Hernández, J.M.; Hofmann, W.K.; Mills, K.I.; et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 2010, 28, 2529–2537. 24. Liu, W.M.; Li, R.; Sun, J.Z.; Wang, J.; Tsai, J.; Wen, W.; Kohlmann, A.; Williams, P.M. PQN and DQN: Algorithms for expression microarrays. J. Theor. Biol. 2006, 243, 273–278. 25. Partek Incorporated. Partek® Genomics SuiteTM Software. 2011. Available online: http://www.partek.com/partekgs (accessed on 19 December 2011). 26. Storey, J.D. The positive false discovery rate: A Bayesian interpretation and the q-value. Ann. Stat. 2003, 31, 2013–2035. 27. Rager, J.E.; Lichtveld, K.; Ebersviller, S.; Smeester, L.; Jaspers, I.; Sexton, K.G.; Fry, R.C. A toxicogenomic comparison of primary and photochemically altered air pollutant mixtures. Environ. Health Perspect. 2011, 119, 1583–1589.